Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.54 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.53 |
| ▸ | WEE1 | P30291 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915907 | 0.83 | FGFR1 (0.63) | BRD4EGFRFGFR1WEE1ALK | |
| SCHEMBL11916385 | 0.83 | FGFR1 (0.63) | BRD4EGFRFGFR1WEE1ALK | |
| SCHEMBL11916391 | 0.81 | CDK1 (0.62) | EGFRSYKCDK1 | |
| SCHEMBL11915885 | 0.78 | PKMYT1 (0.74) | BRD4EGFRPKMYT1ALKCTSC | |
| SCHEMBL19203832 | 0.76 | FGFR1 (0.64) | BRD4EGFRFGFR1WEE1ALK | |
| SCHEMBL11916428 | 0.74 | CCNK (0.65) | BRD4EGFRPKMYT1ALKSYK | |
| SCHEMBL29989713 | 0.73 | JAK2 (0.61) | BRD4FGFR1PKMYT1SYKSTAT6 | |
| SCHEMBL27087812 | 0.73 | JAK2 (0.61) | BRD4FGFR1PKMYT1SYKSTAT6 | |
| SCHEMBL11916311 | 0.72 | FGFR1 (0.51) | EGFRFGFR1WEE1ALKSYK | |
| SCHEMBL11916375 | 0.72 | CDK1 (0.63) | EGFRSYKCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | BRD4 2269/4885EGFR 342/4885FGFR1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.